Literature DB >> 17370257

Proteome informatics for cancer research: from molecules to clinic.

Vladimir Brusic1, Ovidiu Marina, Catherine J Wu, Ellis L Reinherz.   

Abstract

Proteomics offers the most direct approach to understand disease and its molecular biomarkers. Biomarkers denote the biological states of tissues, cells, or body fluids that are useful for disease detection and classification. Clinical proteomics is used for early disease detection, molecular diagnosis of disease, identification and formulation of therapies, and disease monitoring and prognostics. Bioinformatics tools are essential for converting raw proteomics data into knowledge and subsequently into useful applications. These tools are used for the collection, processing, analysis, and interpretation of the vast amounts of proteomics data. Management, analysis, and interpretation of large quantities of raw and processed data require a combination of various informatics technologies such as databases, sequence comparison, predictive models, and statistical tools. We have demonstrated the utility of bioinformatics in clinical proteomics through the analysis of the cancer antigen survivin and its suitability as a target for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17370257     DOI: 10.1002/pmic.200600965

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  8 in total

1.  Role of Fas-associated death domain-containing protein (FADD) phosphorylation in regulating glucose homeostasis: from proteomic discovery to physiological validation.

Authors:  Chun Yao; Hongqin Zhuang; Pan Du; Wei Cheng; Bingya Yang; Shengwen Guan; Yun Hu; Dalong Zhu; Miller Christine; Lv Shi; Zi-Chun Hua
Journal:  Mol Cell Proteomics       Date:  2013-07-04       Impact factor: 5.911

2.  Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.

Authors:  Ovidiu Marina; Ursula Hainz; Melinda A Biernacki; Wandi Zhang; Ann Cai; Jonathan S Duke-Cohan; Fenglong Liu; Vladimir Brusic; Donna Neuberg; Jeffery L Kutok; Edwin P Alyea; Christine M Canning; Robert J Soiffer; Jerome Ritz; Catherine J Wu
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

3.  Differential protein expression analysis using stable isotope labeling and PQD linear ion trap MS technology.

Authors:  Jenny M Armenta; Ina Hoeschele; Iulia M Lazar
Journal:  J Am Soc Mass Spectrom       Date:  2009-03-04       Impact factor: 3.109

4.  Comparative study on transduction and toxicity of protein transduction domains.

Authors:  T Sugita; T Yoshikawa; Y Mukai; N Yamanada; S Imai; K Nagano; Y Yoshida; H Shibata; Y Yoshioka; S Nakagawa; H Kamada; S-I Tsunoda; Y Tsutsumi
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

5.  Platelet and Haemostasis are the Main Targets in Severe Cases of COVID-19 Infection; a System Biology Study.

Authors:  Mona Zamanian-Azodi; Babak Arjmand; Mohammadreza Razzaghi; Mostafa Rezaei Tavirani; Alireza Ahmadzadeh; Mohammad Rostaminejad
Journal:  Arch Acad Emerg Med       Date:  2021-03-14

6.  Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.

Authors:  Lars Olsen; Benito Campos; Ole Winther; Dennis C Sgroi; Barry L Karger; Vladimir Brusic
Journal:  BMC Med Genomics       Date:  2014-12-08       Impact factor: 3.063

Review 7.  Molecular and biological functions of gingerol as a natural effective therapeutic drug for cervical cancer.

Authors:  Parinaz Zivarpour; Elhameh Nikkhah; Parisa Maleki Dana; Zatollah Asemi; Jamal Hallajzadeh
Journal:  J Ovarian Res       Date:  2021-03-11       Impact factor: 4.234

8.  The Cytotoxicity Mechanism of 6-Shogaol-Treated HeLa Human Cervical Cancer Cells Revealed by Label-Free Shotgun Proteomics and Bioinformatics Analysis.

Authors:  Qun Liu; Yong-Bo Peng; Lian-Wen Qi; Xiao-Lan Cheng; Xiao-Jun Xu; Le-Le Liu; E-Hu Liu; Ping Li
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-11       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.